The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 3, trial of gilteritinib, as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with FLT3-ITD+ AML.
 
Mark J. Levis
Research Funding - Astellas Pharma
 
Mehdi Hamadani
Honoraria - Celgene
Consulting or Advisory Role - Celerant; Janssen Oncology; MedImmune
Speakers' Bureau - Sanofi
Research Funding - Spectrum Pharmaceuticals; Takeda
 
Brent Logan
Consulting or Advisory Role - Celgene; Rockwell Medical; Telesta Therapeutics
 
Matt Rosales
Employment - Astellas Oncology
 
Alexander E. Perl
Consulting or Advisory Role - Actinium Pharmaceuticals; Arog; Asana biosciences; Astellas Pharma; Daiichi Sankyo; Novartis; Pfizer; Seagen
 
Steven Michael Devine
Honoraria - Bristol-Myers Squibb; Incyte; Kiadis Pharma
Consulting or Advisory Role - Bristol-Myers Squibb; Incyte; Kite, a Gilead company
Research Funding - Celldex; Sanofi
 
Erkut Bahceci
Employment - Astellas Pharma
 
Yi-Bin Albert Chen
Honoraria - Bayer; Millennium
Consulting or Advisory Role - EnGeneIC; Insys Therapeutics; Jazz Pharmaceuticals; Magenta Therapeutics; Regimmune; Seagen; Takeda; Takeda
Research Funding - Bayer; Celgene; Novartis; Seagen